Prometheus adjustable gene therapy platform
Gene therapy platform
A gene therapy platform delivering therapeutic genes via adeno-associated virus (AAV) and lipid nanoparticle (LNP) vectors in a single injection whose dose can be adjusted, intended to replace ongoing subcutaneous protein therapy with one durable, localized treatment.
- Single-injection, dose-adjustable gene therapy
- Uses established AAV and lipid nanoparticle delivery vectors
- Localized and durable administration replacing repeated subcutaneous protein dosing
- Applied to clinically validated targets rather than novel biology
- Established manufacturing pathway
Built for
Patients with chronic high-prevalence conditions — obesity and Type 2 diabetes, osteoarthritis, and ischemic stroke — reached through clinicians, health systems, and pharmaceutical partners